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Abstract: Amino acid precursors of dopamine and serotonin have been administered for decades 
to treat a variety of clinical conditions including depression, anxiety, insomnia, obesity, and 
a host of other illnesses. Dietary administration of these amino acids is designed to increase 
dopamine and serotonin levels within the body, particularly the brain. Convincing evidence 
exists that these precursors normally elevate dopamine and serotonin levels within critical brain 
tissues and other organs. However, their effects on urinary excretion of neurotransmitters are 
described in few studies and the results appear equivocal. The purpose of this study was to 
deﬁ  ne, as precisely as possible, the inﬂ  uence of both 5-hydroxytryptophan (5-HTP) and tyrosine 
on urinary excretion of serotonin and dopamine in a large human population consuming both 
5-HTP and tyrosine. Curiously, only 5-HTP exhibited a marginal stimulatory inﬂ  uence on urinary 
serotonin excretion when 5-HTP doses were compared to urinary serotonin excretion; however, 
a robust relationship was observed when alterations in 5-HTP dose were compared to alterations 
in urinary serotonin excretion in individual patients. The data indicate three statistically discern-
ible components to 5-HTP responses, including inverse, direct, and no relationships between 
urinary serotonin excretion and 5-HTP doses. The response to tyrosine was more consistent but 
primarily yielded an unexpected reduction in urinary dopamine excretion. These data indicate 
that the urinary excretion pattern of neurotransmitters after consumption of their precursors is 
far more complex than previously appreciated. These data on urinary neurotransmitter excretion 
might be relevant to understanding the effects of the precursors in other organs.
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Introduction
Two critical neurotransmitters, serotonin (5-hydroxytryptamine; 5-HT) and dopamine, 
are synthesized from the amino acids tryptophan and tyrosine, respectively.1,2 Serotonin 
synthesis in vivo is accomplished by a two-step process converting tryptophan to 
5-hydroxytryptophan (5-HTP), facilitated by the enzyme tryptophan hydroxylase, and 
5-HTP is then decarboxylated by dihydroxyphenalanine (DOPA) decarboxylase to 
form serotonin. Tyrosine is converted to dopamine by the combined action of tyrosine 
hydroxylase to form DOPA and DOPA decarboxylase to form dopamine. The synthesis 
of serotonin is commonly stimulated by dietary delivery of L-5-hydroxytryptophan 
(5-HTP)3 and dopamine synthesis is stimulated by dietary administration of either 
tyrosine or L-dihydroxyphenylalanine (L-DOPA).4 Protein-containing foods such as 
meat and dairy products are good natural sources of both tyrosine and tryptophan.
Both 5-HTP and tyrosine are available in the United States as dietary supplements. 
These agents are utilized as natural supplements to augment brain levels of either serotonin Neuropsychiatric Disease and Treatment 2009:5 228
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or dopamine. This study investigates the effects of 5-HTP 
and tyrosine ingestion on urinary excretion of serotonin and 
dopamine in a large sample of humans ingesting 5-HTP and 
tyrosine. Curiously, the urinary excretion of these compounds 
after ingestion of 5-HTP or tyrosine has only been reported in 
human trials involving very small patient cohorts and the results 
involve anomalous responses.5–7 Therefore, this study was 
designed to critically test the hypothesis that increased ingestion 
of 5-HTP or tyrosine elevates urinary excretion of serotonin 
and dopamine, respectively. The purpose of the study was to 
determine if urinary excretion of serotonin or dopamine reﬂ  ect 
the adequacy of supplementation with 5 HTP or tyrosine.
Methodology
The study included 824 individuals ingesting 5-HTP, tyrosine, 
both 5-HTP and tyrosine, or neither. Multiple urine samples 
were obtained from all of these individuals and most received 
multiple doses of supplements to enable comparisons 
between doses of supplements and urinary excretion of 
mature neurotransmitters, as well as the relationship between 
changes in doses and changes in urinary neurotransmit-
ter excretion. The primary rationale for using the dietary 
supplements was weight loss although a signiﬁ  cant number of 
patients were treated for diseases other than obesity that were 
caused by, or associated with, serotonin and/or dopamine 
dysfunction. The participants resided throughout the United 
States. The dose range for 5-HTP ranged from 0 to 2700 mg 
per day. Tyrosine was taken in doses of 0 to 17,000 mg per 
day. The supplements were taken in divided doses two, three, 
or four times a day depending on the dosing of amino acid 
precursors administered.
Urine samples were collected six hours prior to bedtime 
with 4:00 PM being the most frequent collection time point. The 
samples were obtained in 6 N HCl to preserve dopamine and 
serotonin. The urine samples were collected after a minimum 
of one week at a speciﬁ  c dose of the precursor being consumed. 
Samples were shipped to DBS Laboratories (Duluth, MN, 
USA) under the direction of one of the authors (Dr Thomas 
Uncini, a hospital-based dual board certiﬁ  ed laboratory patholo-
gist). Urinary dopamine and serotonin were assayed utilizing 
commercially available radioimmunoassay kits (3 CAT RIA 
IB88501 and IB89527; Immuno Biological Laboratories, Inc., 
Minneapolis, MN, USA). The DBS Laboratories are accred-
ited as a high complexity laboratory by Clinical Laboratory 
Improvement Amendments (CLIA) to perform these assays.
Statistical evaluations utilized either two-way ANOVA 
to compare dose-response curves or regression analyses to 
establish correlations between precursor doses and urinary 
excretion of serotonin and dopamine. We also correlated 
changes in precursor doses with changes in urinary neu-
rotransmitter levels. These regression analyses were con-
ducted to determine if a statistically deﬁ  nable relationship 
existed between dose of precursor and excretion of the 
resulting neurotransmitter. Comparison of mean values 
was performed using Student’s t test. Data are presented as 
individual data points or as means ± SE. A p value  0.05 
was considered statistically signiﬁ  cant. JMP (SAS Institute, 
Cary, NC, USA) software was used to perform the statistical 
analysis.
Data were evaluated further by subdividing responses 
into the following: 1) those representing inverse relationships 
between dietary supplement intake and urinary excretion 
of neurotransmitter, deemed phase 1; 2) those exhibiting 
no relationship between dietary supplement intake and 
neurotransmitter excretion, deemed phase 2; and 3) those 
exhibiting a direct relationship between dietary supplement 
consumption and neurotransmitter excretion in the urine 
(phase 3). These groups were identiﬁ  ed by dividing altera-
tions in neurotransmitter excretion by alterations in supple-
ment dose to obtain the slope of the relationship. Phases 1, 
2, and 3 had negative, 0, and positive slopes, respectively. 
These curves were compared by two-way ANOVA. They 
also were compared with daily ﬂ  uctuations in urinary neu-
rotransmitter efﬂ  ux in the absence of supplement ingestion 
(ie, phase 0). This analysis was performed to determine if the 
alterations in serotonin or dopamine excretion in phases 1, 
2, or 3 could be accounted for by circadian rhythms and/or 
daily ﬂ  uctuations in neurotransmitter excretion resulting from 
stress or other factors. The latter comparison involved the 
Students t test comparing the absolute value of deviations 
in neurotransmitter excretion in all groups. The conversion 
to absolute values was necessary because samples contained 
both positive and negative alterations in neurotransmitter 
excretion that conformed to the appropriate response for a 
speciﬁ  c phase. For instance, a reduction in precursor dose in 
phase 3 resulted in a reduction in neurotransmitter excretion. 
Although the change in neurotransmitter excretion was nega-
tive in this example, it represented the appropriate directional 
change for samples in phase 3.
This study was exempt from Institutional Review Board 
review at the University of Minnesota because it was a ret-
rospective study of deidentiﬁ  ed data.
Results
The dose response to 5-HTP on urinary serotonin excretion is 
shown in Figure 1. The correlation between 5 HTP doses and Neuropsychiatric Disease and Treatment 2009:5 229
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urinary sertotonin excretion was not statistically signiﬁ  cant 
(r = 0.040; p = 0.09). All of these individuals also were 
consuming tyrosine, therefore we sought an interaction with 
tyrosine as well, but there was none (p = 0.50). Surprisingly, 
the data from these experiments indicate only a marginal 
relationship between administration of a serotonin precursor 
and urinary excretion of serotonin.
We then sought a more convincing relationship by ana-
lyzing the effect of 5-HTP dosing alterations on changes 
in urinary serotonin excretion in individual patients. These 
experiments were conceived to ascertain whether individu-
als exhibited dramatically different basal levels of urinary 
serotonin excretion but consistently responded to changes in 
precursor administration with increased excretion of the sero-
tonin. Figure 2 depicts a statistically signiﬁ  cant relationship 
between changes in 5-HTP administration and alterations in 
urinary efﬂ  ux of serotonin (p  0.0001; r = 0.145). These 
data indicate a relationship between ingested 5-HTP and 
urinary serotonin excretion, but this effect remains modest 
based on the regression coefﬁ  cient.
Further examination of the data in Figure 2 indicated 
that, of the 1671 individual data points, 390 demonstrated 
an inverse relationship between changes in urinary serotonin 
excretion and 5-HTP administration, 375 showed virtually no 
change in urinary serotonin excretion (ie, an alteration of less 
than 2000 μg/g creatinine) after altering the 5-HTP dose and 
860 experienced the anticipated direct relationship between 
changes in urinary serotonin excretion and 5-HTP dose. 
Furthermore, 46 samples represented the random variation 
in urinary serotonin excretion when no 5-HTP or tyrosine 
dosing occurred. Thus the relationship between alterations 
in 5-HTP dose and urinary serotonin excretion demonstrated 
in Figure 2 appears to derive from three distinct responses 
being summed in the data presented. The average value of 
each of these three different responses, plus the random daily 
ﬂ  uctuation in the absence of precursors, is shown in Figure 3. 
The results in the absence of any alteration in 5-HTP dose 
(ie, normal circadian rhythms or other disturbances) are 
compared to those representing the three different responses 
when 5-HTP dosing was varied. This comparison was neces-
sary to determine if there is a de facto statistical difference 
between the different patterns of responses and whether the 
responses are distinctly different than random ﬂ  uctuations in 
serotonin excretion. The data are presented as absolute values 
of changes in serotonin excretion because the magnitude 
of the change in serotonin excretion is the critical variable. 
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Figure 1 Relationship between 5-hydroxytryptophan (5-HTP) dose and urinary serotonin (5-HT) excretion. All data represent individual values from patients providing multiple 
samples over time. N represents the total number of samples and the regression coefﬁ  cient was not statistically signiﬁ  cant (p = 0.09).Neuropsychiatric Disease and Treatment 2009:5 230
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Figure 2 Relationship between change in 5-hydroxytryptophan (5-HTP) dose and change in urinary serotonin (5-HT) excretion.   All values are individual points obtained 
from patients providing multiple samples over time.   A statistically signiﬁ  cant relationship was identiﬁ  ed by linear regression (p  0.0001). The equation describing the linear 
regression is provided in the ﬁ  gure.
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Figure 3 Absolute change in serotonin (5-HT) excretion when responses are segregated by change in urinary serotonin excretion as follows: no 5-hydroxytryptophan (5-HTP) 
dose (phase 0); inverse responses of urinary serotonin excretion to changes in 5-HTP (phase 1); no change in urinary serotonin excretion in response to changes in 5-HTP 
dose (phase 2); and direct correlation between changes in urinary serotonin excretion and changes in 5-HTP dose (phase 3).   All values are means + SE.   Values in both phases 1 
and 3 were greater than phases 0 (random ﬂ  uctuation) or 2 (***p  0.0001). Phase 2 responses were less than phase 0 (***p  0.001) and the N was 375.Neuropsychiatric Disease and Treatment 2009:5 231
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As shown in Figure 3, both phase 1 (inverse correlation 
between altered 5-HTP dosing and serotonin excretion) and 
phase 3 (direct correlation between altered 5-HTP dosing and 
serotonin excretion) had much larger, statistically signiﬁ  cant 
variations in comparison to the values representing random 
ﬂ  uctuation of serotonin excretion (indicated as phase 0) 
(p  0.0001 both phases). Phase 2 responses (ie, indicative 
of virtually no change in serotonin excretion in response to 
a change in 5-HTP administration) also were statistically 
different from either phases 0, 1, or 3 (p  0.0001).
The dose-response curves for 5-HTP vs. urinary 
serotonin excretion for the three phases are shown in Figure 
4. The 5-HTP suppressed urinary serotonin excretion in the 
phase 1 samples and augmented excretion in the phase 3 
samples. The phase 0 and phase 2 samples had extremely 
low urinary serotonin levels and the concentrations did not 
ﬂ  uctuate in response to alterations in 5-HTP dosing. Phase 2 
values were signiﬁ  cantly lower than urinary serotonin levels 
in either phase 1 or phase 3 samples (p  0.0001) and 
the slopes of the curves for phases 1, 2, and 3 differed 
signiﬁ  cantly (p  0.0022). Urinary serotonin excretion in 
the absence of 5-HTP dosing was statistically higher in the 
phase 1 samples than any of the other groups. This ﬁ  nding 
is consistent with the phase 1 group demonstrating large 
declines in urinary serotonin levels in response to increased 
administration of 5-HTP. The stimulatory effect of 5-HTP 
observed in phase 3 samples occurred primarily in the dose 
range of 150 to 900 mg 5-HTP. A maximal effect appeared 
to be achieved at the 900 mg 5-HTP dose and no further 
increment in urinary serotonin concentrations was observed 
at higher 5-HTP doses.
Tyrosine ingestion produced a scenario starkly differ-
ent from the 5-HTP data. Tyrosine consistently produced 
a paradoxical effect to reduce urinary dopamine excretion. 
The effect of tyrosine is shown in Figure 5. The inhibitory 
effect of tyrosine was statistically signiﬁ  cant and yielded a 
concentration-dependent effect based on linear regression 
analysis (p  0.0001, R = 0.086).
As with the relationship between 5-HTP consumption and 
serotonin excretion, the tyrosine effect on urinary dopamine 
excretion represented a summation of responses exhibiting 
one of the following: an inverse correlation; no effect; or a 
direct correlation. These data are shown in Figure 6. Con-
sistent with the data shown in Figure 5, the ﬂ  uctuations in 
dopamine excretion were smaller in samples obtained from 
patients ingesting incrementally greater amounts of tyro-
sine; and this difference for the combined phases 1, 2, and 3 
reached a high level of statistical signiﬁ  cance (p  0.0001) 
when compared to phase 0 samples. The ﬂ  uctuations in the 
phase 2 samples were less than any other phase (p  0.005). 
The levels in phase 1 and 3 samples were not statistically 
different from levels in phase 0 samples (p = 0.09 for both). 
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Figure 4 Inﬂ  uence of 5-hydroxytryptophan (5-HTP) dose on urinary excretion of serotonin (5-HT).   All values are means ± SE.   The number of samples in each phase is 
indicated in parentheses. The slopes of the curves differed statistically for phases 1, 2, and 3 (p = 0.0022). Urinary serotonin levels for both phases 1 and 3 were signiﬁ  cantly 
greater than phase 2 by analyses of variance (***p  0.0001), but did not differ from each other.Neuropsychiatric Disease and Treatment 2009:5 232
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These data add support to the surprising observation that 
tyrosine ingestion suppresses urinary dopamine excretion.
The relationship between tyrosine doses and urinary 
dopamine excretion in the three response phases is shown 
in Figure 7. These data were presented as mean data with 
standard errors for clarity necessitated by substantial overlap 
of raw data points. Phase 1 responses were characterized by 
decreasing excretion of dopamine as tyrosine doses increased. 
The slope of this curve was negative and statistically differ-
ent from the curves representing phases 2 or 3 (p  0.0001). 
Phase 2 and 3 did not exhibit statistically discernable slopes 
(p = 0.32), but the urinary dopamine levels were statistically 
greater in phase 3 samples (p = 0.0007).
Discussion
The data presented in this study indicate that consumption 
of speciﬁ  c dietary precursors of serotonin or dopamine only 
increases the urinary excretion of these neurotransmitters 
approximately 50% of the time. Probably the most surprising 
ﬁ  nding of this study is that 20% to 40% of these same individ-
uals respond to the precursors with an unexpected reduction 
in excretion of the neurotransmitters, particularly dopamine. 
These observations indicate that the simplistic expectation 
that increased ingestion of neurotransmitter precursors will 
increase excretion of the mature neurotransmitters in the urine 
is frequently not observed. In fact, the prominent response to 
tyrosine was a suppression of dopamine excretion.
The uncoupling of neurotransmitter excretion from the 
ingestion of precursors for the neurotransmitter is most likely 
caused by the degradation of blood-borne neurotransmitter 
in the kidney.8,9 Most of the serotonin or dopamine found 
in the urine is synthesized in the kidney.9–12 Therefore, the 
excreted neurotransmitters must be synthesized in the kidneys 
and escape reabsorption into the blood in order to be excreted 
in the urine. Most of the serotonin formed by the kidneys is 
typically catabolized2 or reabsorbed and not excreted in the 
urine.8,11,13 Alternatively, dopamine synthesized in the kidney 
is secreted across the apical surface into the urine14 probably 
by an organic cation transporter9,15 resulting in greater urinary 
than interstitial dopamine concentrations.12,13 Larger doses 
of tyrosine and 5-HTP have been observed to increase both 
urinary dopamine and serotonin excretion.16–18 The array 
of catabolic and reabsorptive events probably accounts for 
the far more complex responses than expected to 5-HTP or 
tyrosine ingestion observed in this study.
In spite of the complex sequence of renal events account-
ing for the appearance of neurotransmitter in urine, the pres-
ence of opposing responses (ie, phases 1 and 3) does not seem 
possible without a direct effect of either the precursors or the 
formed neurotransmitters to cause an aberration in the series 
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Figure 5 Effect of tyrosine on urinary dopamine excretion. All values are individual data points from patients ingesting tyrosine. Tyrosine signiﬁ  cantly suppressed urinary 
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of events leading to the presence of urinary neurotransmitters. 
Based on a large volume of studies in the literature, it is 
likely that administration of 5-HTP increases the synthesis 
of serotonin within the kidney.2,3,8 Transporters for serotonin 
then transfer it into the blood stream to prevent it from being 
excreted in the urine. The phase 1 response we observed for 
serotonin could be explained by either a neurotransmitter-
induced allosteric alteration of a reabsorptive transporter 
to increase activity or an induction of the synthesis of the 
transporter. Increased transport of the neurotransmitters out 
of the region of the nephron would theoretically reduce uri-
nary excretion of the neurotransmitter, as observed in phase 
1. If the alteration or induction were great enough, essentially 
all of the neurotransmitter would be reabsorbed and little 
or none would appear in the urine, as observed in phase 2. 
A conversion to phase 3 would be possible if the supply of 
neurotransmitter eventually increased enough to saturate the 
transport process and result in spillage of neurotransmitter 
into the urine. All three phases have been observed in the 
same individual and the three phases could represent different 
stages of renal processing of 5-HTP. We currently have no 
evidence explaining the different phases and the potential for 
increased activity or induction of neurotransmitter transport-
ers merely appears to be the most likely possibility explaining 
these observations at this point in time.
The response to tyrosine was dominated by suppressed 
urinary dopamine excretion. This scenario probably neces-
sitates either an inhibition of dopamine secretion into the 
nephron lumen or a reduction in renal dopamine synthesis. 
Two reports indicate that newly synthesized dopamine is 
normally secreted into the nephron,12,13 thus an inhibition 
of this secretion could account for the inhibitory effect. It 
is likely that tyrosine could interfere with the secretion of 
dopamine into the lumen of the nephron but we are unaware 
of any reports supporting this site of action.
Tyrosine appears to be an unlikely inhibitor of renal 
dopamine synthesis because it is widely recognized as a 
dopamine precursor. However, tyrosine suppresses L-DOPA 
uptake into proximal tubule cells14,19 and L-DOPA uptake 
is required for renal dopamine synthesis.20 L-DOPA is the 
immediate precursor to dopamine in the synthetic pathway; 
therefore, inhibition of its uptake could impair dopamine 
synthesis. Proximal tubule cells accumulate tyrosine14 but 
the kidney lacks extraneuronal tyrosine hydroxylase1,21,22 and 
cannot convert it to dopamine. Thus, tyrosine could have a 
paradoxical inhibition of dopamine synthesis in the kidney 
by suppressing L-DOPA uptake into proximal tubule cells. 
This scenario represents a potential mechanism accounting 
for phase 1 responses to tyrosine. An alternative scenario 
potentially accounting for phase 3 responses to tyrosine 
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Figure 6 The average change in urinary dopamine excretion from baseline in the different phases including random ﬂ  uctuation of dopamine excretion (phase 0).   All values 
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involves the peripheral conversion of tyrosine to L-DOPA 
in neuronal tissue. The L-DOPA entering the kidney could 
serve as a precursor to dopamine and result in increased 
dopamine secretion observed in phase 3. The observation 
of the inhibitory (ie, phase 1) response to tyrosine has not 
been reported previously. A plethora of reports indicate that 
phase 3 stimulatory effects of tyrosine on urinary dopamine 
excretion is the predominant response in most studies in 
rats4,22,23 and protein has been widely used as a tyrosine 
source to increase dopamine excretion in humans.24 It is 
possible that the phase 1 response to tyrosine in humans has 
not been noted previously because of the limited number of 
studies speciﬁ  cally investigating tyrosine effects on human 
dopamine excretion.
The novel observations noted in this study include a 
somewhat variable relationship between ingested 5-HTP and 
urinary serotonin excretion and the unexpected inf  luence 
of tyrosine to reduce urinary dopamine excretion. The 
description of the three phases demonstrating the relation-
ship between 5-HTP and urinary serotonin excretion is also 
novel and probably is a reﬂ  ection of serotonin reabsorption 
in the kidney. The consistent and statistically discernable 
ability of tyrosine to dampen ﬂ  uctuations in urinary dopa-
mine excretion is also noteworthy. These processes might be 
ref lective of similar processes occurring in other organs and 
suggest that urine sampling for neurotransmitters requires 
multiple samples to determine the direction of the response 
and, potentially, the adequacy of dosing.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
 1. Blaschko H. The activity of L(-)-DOPA decarboxylase. J Physiol. 
1942;101:337–349.
 2. Udenfriend S, Titus E, Weissbach H, Peterson RE. Biogenesis 
and metabolism of 5-hydroxyindole compounds. J Biol Chem. 
1956;219:335–344.
  3.  Udenfriend S, Weissbach H, Bogdanski DF. Increase in tissue serotonin 
following administration of its precursor 5-hydroxytryptophan. J Biol 
Chem. 1957;224:803–810.
 4. Agharanya JC, Wurtman RJ. Studies on the mechanism by which 
tyrosine reaises urinary catecholamines. Biochem Pharmacol. 
1982;31:3577–3580.
 5. Arterberry JD, Conley MP. Urinary excretion of serotonin 
(5-hydroxytryptamine) and related indoles in normal subjects. Clin 
Chim Acta. 1967;17:431–440.
 6. Takahashi S, Takahashi R, Masumura I, Milke A. Measurement of 
5-Hydroxyindole compounds during L-5-HTP treatment in depressed 
patients. Folia Psychiatr Neurol Jpn. 1976;30:463–473.
 7. Kema IP, Schellings AMJ, Hoppenbrouwers CJM, Rutgers HM, 
de Vries EGE, Muskiet FAJ. High performance liquid chromatorgraphic 
proﬁ  ling of tryptophan and related indoles in body ﬂ  uids and tissues of 
carcinoid patients. Clin Chim Acta. 1993;221:143–158.
15000 10000 5000 0
0
100
200
300
400
500
600
700
800
900
Phase 1 (520)
Phase 2 (117)
Phase 3 (638)
Tyrosine (mg/day)
U
r
i
n
a
r
y
 
d
o
p
a
m
i
n
e
 
(
µ
g
/
g
 
c
r
e
a
t
i
n
i
n
e
)
***
Figure 7 The relationship between tyrosine administration and urinary dopamine excretion for the different phases of dopamine excretion. The number of samples per group 
is indicated in parentheses.   All values are means ± SE. The slope for phase 1 differed signiﬁ  cantly from slopes for phases 2 or 3 (***p  0.0001).Neuropsychiatric Disease and Treatment 2009:5 235
Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan 
  8.  Davidson J, Sjoerdsma A, Loomis LN, Udenfriend S. Studies with the 
serotonin precursor, 5-hydroxytryptophan, in experimental animals and 
man. J Clin Invest. 1957;36:1594–1599.
 9. Graefe K-H, Friedgen B, Wolfel R, Bossle F, Russ H, Schomig E. 
1,1’-Diisopropyl-2,4’-cyanine (disprocynium24), a potent uptake2 
blocker, inhibits the renal excretion of catecholamines. Naunyn Schmie-
debergs Arch Pharmacol. 1997;356:115–125.
10. Wa TCLK, Burns NJT, Williams BC, Freestone S, Lee MR. Blood 
and urine 5-hydroxytryptophan and 5-hydroxytryptamine levels after 
administration of two 5-hydroxytryptamine precursors in normal man. 
Br J Clin Pharmacol. 1995;39:327–329.
11.  Stier CT, Brewer TF, Dick LB, Wynn N, Itskovitz HD. Formation of 
biogenic amines by isolated kidneys of spontaneously hypertensive 
rats. Life Sci. 1986;38:7–14.
12. Wang Z-Q, Siragy HM, Felder RA, Carey RM. Intrarenal dopamine 
production and distribution in the rat. Hypertension. 1997;29(1 Pt 2):
228–234.
13.  Berndt TJ, Liang M, Tyce GM, Knox FG. Intrarenal serotonin, 
dopamine and phosphate handling in remnant kidneys. Kidney Int. 
2001;59:625–630.
14.  Chan YL. Cellular mechanisms of renal tubular transport of L-DOPA 
and its derivative in the rat: microperfusion studies. J Pharmacol Exp 
Ther. 1976;199:17–24.
15. Gründemann D, Köster S, Kiefer N, et al. Transport of monoamine 
transmitters by the organic cation transporter type 2, OCT2. J Biol 
Chem. 1998;273:30915–30920.
16.  Baines AD, Craan A, Morgunov N. Tubular secretion and metabolism 
of dopamine, norepinephrine, methoxtyramine and normetanephrine 
by the rat kidney. J Pharmacol Exp Ther. 1979;208:144–147.
17. Wa TCLK, Freestone S, Samson RR, Johnston NR, Lee MR. 
A comparison of the effects of two putative 5-hydroxytryptamine renal 
prodrugs in normal man. Br J Clin Pharmacol. 1993;36:19–23.
18. Agharanya JC, Alonso R, Wurtman RJ. Changes in catecholamine 
excretion after short-term tyrosine ingestion in normally fed human 
subjects. Am J Clin Nutr. 1981;34:82–87.
19. Soares-da-Silva P, Serrao MP, Pinho MJ, Vonifacio MJ. Cloning an 
gene silencing of LAT2, the L-3,4-dihydroxyphenylalanine (L-DOPA) 
transporter, in pig renal LLC-PK1 epithelial cells. FASEB J. 2004;18:
1489–1498.
20. Soares-da-Silva P, Fernandes H. Sodium-dependence and oubain 
sensitivity of the synthesis of dopamine in renal tissues of the rat. Br J 
Pharmacol. 1992;105:811–816.
21.  Nagatsu T, Rust LA, DeQuattro V. The activity of tyrosine hydroxylase 
and related enzymes of catecholamine biosynthesis and metabolism 
in dog kidney. Effects of denervation. Biochem Pharmacol. 1969;18:
1441–1446.
22.  Muhlbauer B, Gleiter CH, Gies C, Luippold G, Loschmann P-A. Renal 
response to infusion of dopamine precursors in anaesthetized rats. 
Naunyn Schmiedebergs Arch Pharmacol. 1997;356:838–845.
23.  Muhlbauer B, Mickeler C, Schenk F. Protein-induced increase in urinary 
dopamine in normal and diabetic rats: role of catecholamine precursors. 
Am J Physiol. 1997;273:F80–R85.
24.  Williams M, Young JB, Rosa RM, Gunn S, Epstein FH, Landsberg L. 
Effect of protein ingestion on urinary dopamine excretion. J Clin Invest. 
1986;78:1687–1693.